Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 45.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.57M.
Undervalued
The company’s latest PE is -8.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.57M shares, decreasing 17.72% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.